Inspire Veterinary Faces Nasdaq Delisting, Moves OTC

Inspire Veterinary Partners, Inc. announced that a Nasdaq Hearings Panel has denied its request to continue listing on Nasdaq after the company failed to meet the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2).

Rhea-AI Filing Summary

Inspire Veterinary Partners, Inc. announced that a Nasdaq Hearings Panel has denied its request to continue listing on Nasdaq after the company failed to meet the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). As a result, its common stock was suspended from trading on The Nasdaq Capital Market at the open on January 21, 2026 and will be delisted, with Nasdaq expected to file a Form 25 to remove the securities from listing and registration. The company has received approval for its common stock to trade on the OTCQB Venture Market under the symbol “IVPR,” where trading also began on January 21, 2026. Inspire Veterinary states that it intends to continue filing periodic reports with the SEC.

Positive

• None.

Negative

• Nasdaq delisting and trading suspension: A Nasdaq Hearings Panel denied continued listing, the stock was suspended from The Nasdaq Capital Market on January 21, 2026 and will be formally delisted, which typically reduces liquidity and visibility.

Insights

Equity markets and listing standards analyst

Nasdaq delisting is a clear negative, partially offset by an OTCQB move.

Inspire Veterinary Partners confirms that a Nasdaq Hearings Panel denied its appeal to remain listed after prior non-compliance with the minimum bid price rule. Trading on The Nasdaq Capital Market was suspended at the open on January 21, 2026, and the company expects Nasdaq to file Form 25 to complete the delisting.

The shares are now quoted on the OTCQB Venture Market under symbol “IVPR,” which generally offers lower visibility and potentially reduced liquidity compared with a national exchange. The company indicates it intends to continue filing periodic reports with the SEC, so investors will still have access to ongoing public disclosures.

The key implications are reduced exchange prestige and possible constraints on institutional ownership or research coverage, typical of moves from Nasdaq to OTC venues. Future company filings and trading activity on OTCQB will help show how this new trading venue affects investor participation.

8-K Event Classification

2 items: 3.01, 8.01

2 items

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Securities

The company received a delisting notice, failed to satisfy a continued-listing rule or standard, or transferred its listing.

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Why was Inspire Veterinary Partners (IVP) delisted from Nasdaq?

Inspire Veterinary Partners was previously notified that it was not in compliance with Nasdaq Listing Rule 5550(a)(2) because its common stock’s closing bid price was below the required minimum for 30 consecutive business days. After a hearing on January 13, 2026, a Nasdaq Hearings Panel denied the company’s request to continue its listing.

When did Inspire Veterinary Partners’ common stock stop trading on Nasdaq?

Inspire Veterinary Partners’ common stock was suspended from trading on The Nasdaq Capital Market at the open of trading on January 21, 2026, following the Nasdaq Hearings Panel’s decision.

Where does Inspire Veterinary Partners’ stock trade now and under what symbol?

The company’s common stock has been approved to trade on the OTCQB Venture Market under the trading symbol “IVPR”, and began trading there on January 21, 2026.

Will Inspire Veterinary Partners continue filing reports with the SEC after the Nasdaq delisting?

Yes. Inspire Veterinary Partners states that it intends to continue to file periodic reports with the SEC, even though its common stock will no longer be listed on Nasdaq.

What regulatory step is expected next in Inspire Veterinary Partners’ delisting process?

The company expects Nasdaq to file a Form 25 with the SEC, which will remove its securities from listing and registration on Nasdaq.

Did Inspire Veterinary Partners appeal the initial Nasdaq non-compliance notice?

Yes. After receiving a Nasdaq notice on November 13, 2025 regarding minimum bid price non-compliance, the company requested a hearing before a Nasdaq Hearings Panel, which was held on January 13, 2026. The request to continue its listing was ultimately denied.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/21/2026 - 04:15 PM Learn about SEC filing dates

false 0001939365 0001939365 2026-01-20 2026-01-20 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 20, 2026

INSPIRE VETERINARY PARTNERS, INC.

(Exact name of registrant as specified in its charter)

Nevada		001-41792		85-4359258
(State or other jurisdiction		(Commission File Number)		(I.R.S. Employer
of incorporation)				Identification No.)

780 Lynnhaven Parkway, Suite 400 Virginia Beach, VA		23452
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (757) 734-5464

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common stock, par value $0.0001		IVP		Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

As reported previously, on November 13, 2025, Inspire Veterinary Partners, Inc. (the “Company”) received a notice letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, based upon the closing bid price of the Company’s Class A common stock, par value $0.0001 per share (the “Common Stock”), for the prior 30 consecutive business days, the Company was not in compliance with the minimum bid price requirement of Nasdaq Listing Rule 5550(a)(2). The Notice stated that the Company’s securities would be suspended from trading on The Nasdaq Capital Market, unless the Company requested an appeal of such determination to Nasdaq’s Hearings Panel (the “Panel”). The Company requested a hearing, which was held on January 13, 2026 and stayed any further suspension or delisting action by Nasdaq pending the ultimate conclusion of the hearing process.

On January 20, 2026, the Panel denied the Company’s request to continue its listing on Nasdaq. The Common Stock was suspended from trading on The Nasdaq Capital Market at the open of trading on January 21, 2026 and will be delisted from Nasdaq. The Company expects Nasdaq will file a Form 25 with the U.S. Securities and Exchange Commission (“SEC”), which will remove the Company’s securities from listing and registration on Nasdaq.

The Company has received approval for its Common Stock to trade on the OTCQB Venture Market under the trading symbol “IVPR” and the Common Stock began trading on that market on January 21, 2026. The Company intends to continue to file periodic and current reports with the SEC.

Item 8.01 Other Events 

On January 21, 2026, the Company issued a press release announcing that its Common Stock is trading on the OTCQB Venture Market. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item. 9.01 Financial Statements and Exhibits 

Exhibit No.		Description
99.1		Press Release dated January 21, 2026
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

Forward-Looking Statements

This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s Common Stock delisting and trading market and SEC filing obligations. These statements are subject to risks and uncertainties, including market conditions and the Company’s financial condition, that could cause actual results to differ materially. The Company undertakes no obligation to update forward-looking statements except as required by law.

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: January 21, 2026	INSPIRE VETERINARY PARTNERS, INC.
	By:	/s/ Kimball Carr
	Name:	Kimball Carr
	Title:	President and Chief Executive Officer

2